Cryptobiotix
Provider of validated, high-throughput ex vivo gastrointestinal simulation services for preclinical gut microbiome research. The company operates a modular pipeline that simulates upper-GI digestion, colonic fermentation and downstream host interaction to generate mechanistic, dose–response and donor-stratified data intended to inform product development, regulatory dossiers, IP and clinical trial design.
Industries
Nr. of Employees
small (1-50)
Products
Systemic Intestinal Fermentation Research (SIFR)
A research service that evaluates the interaction between products and the gut microbiome, providing insights into mechanisms of action and efficacy through ex vivo simulation.
Gastrointestinal Simulation Model
A model that simulates the human gastrointestinal tract to predict product interactions and outcomes, aiding in product development and regulatory submissions.
NextDext®
A long-chain dextran prebiotic that enhances microbial diversity and health-related gut bacteria, offering potential health benefits.
Preclinical Research Services
Laboratory services focusing on microbiome and gastrointestinal tract research to support the development of novel treatments for human and animal health.
Ecologic® 825
A probiotic formula studied for its effects on the small intestine, showing potential in reducing pathobionts and increasing beneficial metabolites.
Sweeteners Research
A study on the impact of various low/no-calorie sweeteners on the gut microbiota of healthy and type-2 diabetes individuals.
Systemic Intestinal Fermentation Research (SIFR)
A research service that evaluates the interaction between products and the gut microbiome, providing insights into mechanisms of action and efficacy through ex vivo simulation.
Gastrointestinal Simulation Model
A model that simulates the human gastrointestinal tract to predict product interactions and outcomes, aiding in product development and regulatory submissions.
NextDext®
A long-chain dextran prebiotic that enhances microbial diversity and health-related gut bacteria, offering potential health benefits.
Preclinical Research Services
Laboratory services focusing on microbiome and gastrointestinal tract research to support the development of novel treatments for human and animal health.
Ecologic® 825
A probiotic formula studied for its effects on the small intestine, showing potential in reducing pathobionts and increasing beneficial metabolites.
Sweeteners Research
A study on the impact of various low/no-calorie sweeteners on the gut microbiota of healthy and type-2 diabetes individuals.
Services
End-to-end ex vivo studies that simulate digestion, colonic fermentation and host interaction to generate mechanistic, dose–response and stratification data for ingredients, foods, probiotics, postbiotics and drug candidates. Capabilities include synbiotic combination screening, protein-fraction assessment and small-intestine effluent incubation.
High-throughput parallel screening of multiple candidates to identify promising leads and optimal dosing rapidly.
Comprehensive mechanistic characterisation including inter-individual variability, pathway analysis and host response integration to support regulatory filings, IP and clinical study design.
Selection, storage and retrieval of donor microbiota cohorts to enable cohort-relevant testing and faster study initiation.
End-to-end ex vivo studies that simulate digestion, colonic fermentation and host interaction to generate mechanistic, dose–response and stratification data for ingredients, foods, probiotics, postbiotics and drug candidates. Capabilities include synbiotic combination screening, protein-fraction assessment and small-intestine effluent incubation.
High-throughput parallel screening of multiple candidates to identify promising leads and optimal dosing rapidly.
Comprehensive mechanistic characterisation including inter-individual variability, pathway analysis and host response integration to support regulatory filings, IP and clinical study design.
Selection, storage and retrieval of donor microbiota cohorts to enable cohort-relevant testing and faster study initiation.
Expertise Areas
- Preclinical gut microbiome modelling using ex vivo systems
- Host–microbiome interaction assays and organoid-based testing
- Parallel multi-donor cohort testing and responder stratification
- Metabolomics and short-chain fatty acid profiling
Key Technologies
- Ex vivo gastrointestinal simulation
- High-throughput automated laboratory workflows
- Parallel multi-donor cohort incubation
- Quantitative microbiome sequencing (sequence + cell density)
News & Updates
Publication and validation that ex vivo simulations predict in vivo compositional shifts across interventions such as inulin, resistant dextrin and 2'FL.
Study integrating quantitative sequencing and a Community Modulation Score to show a long-chain dextran increases microbial diversity and alters metabolite profiles compared to inulin.
Investigation of milk bioactives using organoid uptake assays and ex vivo digestion/fermentation showing stimulation of SCFAs and specific bacterial taxa in infant-simulated microbiomes.
Ex vivo study showing serum-derived bovine immunoglobulin enhanced gut barrier integrity and lowered TNF-α and CXCL10, with predictive relevance to clinical results.
Large-scale ex vivo study across 24 donor microbiota demonstrating consistent stimulation of indole-3-propionic acid (IPA) and specific enrichment of Bifidobacterium longum.
Ex vivo evaluation of HMOs at low doses showing stimulation of SCFAs and broader metabolomic changes linked to immunity, cardiometabolic and gut–brain axes in adults and children.
Publication and validation that ex vivo simulations predict in vivo compositional shifts across interventions such as inulin, resistant dextrin and 2'FL.
Study integrating quantitative sequencing and a Community Modulation Score to show a long-chain dextran increases microbial diversity and alters metabolite profiles compared to inulin.
Investigation of milk bioactives using organoid uptake assays and ex vivo digestion/fermentation showing stimulation of SCFAs and specific bacterial taxa in infant-simulated microbiomes.
Ex vivo study showing serum-derived bovine immunoglobulin enhanced gut barrier integrity and lowered TNF-α and CXCL10, with predictive relevance to clinical results.
Large-scale ex vivo study across 24 donor microbiota demonstrating consistent stimulation of indole-3-propionic acid (IPA) and specific enrichment of Bifidobacterium longum.
Ex vivo evaluation of HMOs at low doses showing stimulation of SCFAs and broader metabolomic changes linked to immunity, cardiometabolic and gut–brain axes in adults and children.